Table 3.
Adjusted COPD-related costs by cohort
| Cost outcome | FSC | AC | Difference (95% CI) | ||
|---|---|---|---|---|---|
|
|
|
||||
| Mean | 95% CI | Mean | 95% CI | ||
| COPD-related costs | |||||
| Total costs | $1659 | ($757, $3754) | $1677 | ($710, $4087) | −$18 ($47, −$333) |
| Pharmacy costs | $941 | ($526, $1708) | $683 | ($360, $1315) | $258 ($167, $392) |
| Medical costs | $692 | ($84, $4377) | $1042 | ($103, $7511) | −$350 (−$19, −$3134) |
| Hospitalization | $231 | ($5, $2118) | $446 | ($7, $4538) | −$215 (−$2, −$2420) |
| Emergency department visit | $46 | ($3, $502) | $50 | ($2, $525) | −$4 ($1, −$23) |
| Physician visit | $128 | ($25, $477) | $132 | ($21, $554) | −$5 ($4, −$77) |
| Outpatient visit | $118 | ($4, $2651) | $156 | ($4, $4503) | −$38 ($0, −$1852) |
| Other | $176 | ($21, $790) | $199 | ($20, $908) | −$23 ($1, −$118) |
Notes: Bold values indicate statistically significant difference between cohorts (P < 0.05); all costs in USD.
Abbreviations: COPD, chronic obstructive pulmonary disease; FSC, fluticasone propionate/salmeterol 250/50 mcg combination; AC, anticholinergics; CI, confidence interval.